DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial
| Autor: | Christian Primas, Heinz Zoller, I Blumenstein, Walter Reinisch, Tariq Iqbal, L L Thomsen, Myles Wolf, Stefan Lindgren |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Crohn's disease biology business.industry Gastroenterology General Medicine Iron deficiency medicine.disease Ulcerative colitis Inflammatory bowel disease Ferritin Iron-deficiency anemia Internal medicine medicine biology.protein Ferric business Hypophosphatemia medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 15:S121-S121 |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjab073.128 |
| Popis: | Background Intravenous iron can correct iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). Certain formulations are associated with hypophosphatemia, but this has not previously been investigated in a randomised clinical trial in IBD. The aim of this randomised, double-blind trial was to compare the risk of hypophosphatemia with ferric derisomaltose/iron isomaltoside 1000 (FDI) vs ferric carboxymaltose (FCM) in patients with IDA due to IBD. Methods Adults with IBD and IDA (haemoglobin [Hb] Results Of 97 patients enrolled (mean age 42.1 years; 52.6% female; 39.2% Crohn’s disease; 60.8% ulcerative colitis), 48 received FDI and 49 FCM. The incidence of hypophosphatemia was significantly lower for FDI than FCM (8.3% vs. 51.0%; p Conclusion In IDA due to IBD, FDI resulted in significantly lower incidence of hypophosphatemia than FCM. FDI and FCM lead to similar increases in Hb concentration. In contrast to FDI, FCM treatment led to persistent changes in bone biomarkers, suggesting possible long-term adverse effects on bone health. ClinicalTrials.gov Identifier: NCT03466983. Supported by Pharmacosmos A/S (Holbæk, Denmark). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|